ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1602909
This article is part of the Research TopicColorectal Cancer Immunotherapy and Immune MechanismsView all 7 articles
Development and validation of a deep learning-based pathomics signature for prognosis and chemotherapy benefits in colorectal cancer: a retrospective multicenter cohort study
Provisionally accepted- 1Harbin Medical University Cancer Hospital, Harbin, China
- 2The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China
- 3Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The conventional tumor-node-metastasis (TNM) classification system remains limited in accurately forecasting prognosis and guiding adjuvant chemotherapy decisions for patients with colorectal cancer (CRC). To address this gap, we introduced and validated a novel pathomics signature (PSCRC) derived from hematoxylin and eosin-stained whole slide images, leveraging a deep learning framework. This retrospective study analyzed 883 slides from two independent cohorts. An interpretable multi-instance learning model was developed to construct PSCRC, with SHapley Additive exPlanations (SHAP) and gradient-weighted class activation mapping (Grad-CAM) for the improvement of model interpretability and the identification of critical histopathological features, respectively. The transcriptomic data was provided by The Cancer Genome Atlas (TCGA) and integrated to investigate the biological mechanisms underpinning PSCRC. The results demonstrated that PSCRC was proven to be an independent prognostic indicator for both overall and disease-free survival. It significantly enhanced the prognostic performance alongside TNM staging, as shown by improvements in net reclassification and integrated discrimination indices. Furthermore, patients in stages II and III with low PSCRC levels were more likely to benefit from chemotherapy.Morphologically, PSCRC reflected features such as tumor infiltration, adipocyte presence, fibrotic stroma, and immune cell engagement. Transcriptome analysis further revealed links between PSCRC and pathways involved in tumor progression and immune evasion. Our findings suggested that the application of deep learning to histopathological images could be an efficient method to improve the prognostic accuracy and evaluate the treatment responses in CRC. The PSCRC offers a promising aid for clinical decision-making by shedding light on key pathogenic processes.Nevertheless, further validation through prospective studies remains essential.
Keywords: colorectal cancer, deep learning, Whole slide image, Pathology, prognosis
Received: 30 Mar 2025; Accepted: 29 May 2025.
Copyright: © 2025 Lou, Huang, Du, Xue, Mo, Li, Yu, Li, Wang, Huang, Xie, Song, Zhang, Li, Lou and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Huiying Li, Harbin Medical University Cancer Hospital, Harbin, China
Chun Lou, Harbin Medical University Cancer Hospital, Harbin, China
Peng Han, Harbin Medical University Cancer Hospital, Harbin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.